Axovant Gene Therapies Ltd. (AXGT) Fundamentals

Axovant Gene Therapies Ltd is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis. It currently has three clinical-stage programs which include AXO-Lenti-PD program for Parkinson's disease, AXO-AAV-GM1 program for GM1 gangliosidosis, and AXO-AAV-GM1 program for GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases).
SHARE INFORMATION
Market Cap$ 99,224,431
Shares Outstanding47,249,729
Float28,552,669
Percent Float60.43%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -2.93
Latest Fiscal Date2020-03-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions35
Institutional Holdings Date2020-10-31
Institutional Bought Previous 3 Months6,000
Institutional Holdings Percent1.9%
Institutional Sold Previous 3 Months36,509
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned867,404
TRADING INFO
52 Week High$ 6.12
52 Week Low$ 1.41
52 Week High Change$ -59.85
21 Day Moving Average$ 2.871
21 Day Extended Moving Average$ 2.7168
50 Day Moving Average$ 3.5036
50 Day Extended Moving Average$ 3.159
200 Day Moving Average$ 3.2376
200 Day Extended Moving Average$ 3.7304
10 Day Average Volume2,217,661
20 Day Average Volume2,068,467
30 Day Average Volume2,692,943
50 Day Average Volume2,209,392
Alpha-0.039593
Beta1.5327
Standard Deviation0.252936
R20.065210
7 Day Price Change$ -0.12
7 Day Percent Change-5.41%
21 Day Price Change$ -1.39
21 Day Percent Change-39.83%
30 Day Price Change$ -1.58
30 Day Percent Change-42.93%
Month to Date Price Change$ -0.03
Month to Date Percent Change-1.41%
Quarter to Date Price Change$ -2.52
Quarter to Date Percent Change-54.55%
180 Day Price Change$ -1.25
180 Day Percent Change-37.31%
200 Day Price Change$ -1.44
200 Day Percent Change-40.68%
Year to Date Price Change$ -3.02
Year to Date Percent Change-58.98%

Axovant Gene Therapies Ltd. (AXGT) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.70
Total Debt To Equity0.00
Int Coverage-13.60
Current Ratio4.90
Leverage Ratio1.40
Quick Ratio4.60
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio0.00
Enterprise Value$ 45,223,425
Price to Sales0.00
Price to Free Cash-2.20
PE High Last 5 Years0.00
Price To Book1.70
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book1.70
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-62.14
Return on Equity-121.47
Return on Capital-77.31

Axovant Gene Therapies Ltd. (AXGT) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOPavan Cheruvu
Emplyoees38
Last AuditUE
CIK0001636050
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address11-12 St. James's Square
Suite 1, 3rd Floor
London, SW1Y 4LB
Websitehttps://www.axovant.com
Facsimile-
Telephone+44 2039978931
Email-


Your Recent History
NASDAQ
AXGT
Axovant Ge..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.